electroporation therapy

A local treatment modality for malignancy which uses brief, high-intensity, pulsed electrical currents to enhance the uptake of cytotoxic drugs, vaccines, and genes into cells by producing a transient increase in cell wall permeability

electroporation therapy

Therapeutics A form of drug delivery that generates electrical pulses via an electrode placed in a tumor to enhance the ability of a chemotherapeutic–eg, bleomycin to enter tumor cells involves using electric fields to open pores in human cells to allow easier and more efficient entrance of beneficial pharmaceutical products or genes. See Drug delivery, Iontophoresis.

e·lec·tro·po·ra·tion ther·a·py

(EPT) (ĕ-lek'trō-pōr-ā'shŭn thār'ă-pē)
Investigational therapy involving use of electric fields to open pores in human cells; provides for easier and more efficient entry of genes or pharmaceutical products.
Mentioned in ?
References in periodicals archive ?
There is a significant unmet clinical need for an alternative to surgery that selectively destroys cancer cells without harming normal healthy tissue, and I am therefore excited about Genetronics' MedPulser(R) Electroporation Therapy System.
We believe we are in a solid position to continue to execute on the fundamentals that will allow us to advance our electroporation therapy towards commercialization, which is expected to begin in 2005 in Europe.
E[acute accent]Inovio's MedPulser(R) Electroporation Therapy System significantly enhances local cellular uptake of useful biopharmaceuticals, including DNA.
The patent adds to Genetronics' position as a pioneer in the use of electroporation therapy, without drugs, to achieve vasodilation.
Conclude the European pre-marketing clinical study in new and recurrent primary squamous cell carcinoma of the head and neck (SCCHN) to support the commercialization of our MedPulser(R) Electroporation Therapy System in the EU;
The primary endpoint of this FDA-approved study is to determine the safety profile of the MedPulser(R) electroporation therapy in conjunction with intralesionally-injected bleomycin for the treatment of unresectable or incurable locally advanced pancreatic cancer.
The company is moving its lead product, the MedPulser(R) Electroporation Therapy System, through pre-marketing studies for head and neck cancer in Europe, where it has received CE Mark accreditation, and a Phase III pivotal study for recurrent head and neck cancer in the US.
Genetronics Biomedical is a late stage biomedical company focused on building an oncology franchise based on its proprietary electroporation therapy.
For example, our expectations concerning the significance of our patent portfolio and its enhancement by the addition of the license discussed in this press release as a means of facilitating commercialization of DNA therapeutics delivered using electroporation therapy are forward looking statements.
The company is moving its lead product, the MedPulser(R) Electroporation Therapy System, through pre-marketing studies for head and neck cancer and skin cancers in Europe, where it has CE Mark accreditation, a U.
Genetronics is a late stage biomedical company focused on building an oncology franchise based on its proprietary electroporation therapy (EPT).
We have developed two systems for gene delivery, namely the MedPulser(R) DNA Delivery System designed for intramuscular delivery of DNA plasmid and the MedPulser(R) DNA Electroporation Therapy System designed for the delivery of DNA plasmids to tumor tissue.